查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
藥物輸送聚合物市場 - 2023-2028 年預測
市場調查報告書
商品編碼
1295334

藥物輸送聚合物市場 - 2023-2028 年預測

Drug Delivery Polymer Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

藥物輸送聚合物市場預計複合年增長率為 7.55%，從 2021 年的 182.9 億美元增長到 2028 年的 304.44 億美元。

聚合物能夠長時間以固定劑量控制釋放藥物，從而在改善藥物輸送方法方面發揮著重要作用。 由於其生物可降解性和生物相容性，近年來其在生物醫學應用中的使用有所增加。 然而，使用聚合物作為藥物載體提出了重大挑戰，包括複雜的製造和表徵步驟。 生物製藥領域重要的是基於聚合物的藥物遞送，其中藥物、蛋白質和抗體共價連接到線性或支化聚合物上。

此外，由於納米技術領域的研發活動增加，以創造新的納米藥物、產品管道的擴大、有利的研究環境以及癌症和糖尿病等慢性疾病的患病率不斷增加，藥物輸送聚合物市場預計將增長在整個預測期內增長。 然而，由於藥物研究成本上升和嚴格的監管環境，預計市場在整個預測期內將面臨挑戰。

慢性疾病患病率的上升推動了藥物輸送聚合物市場的發展。

全球疾病的增加預計將增加對安全高效的給藥系統的需求。 癌症、糖尿病和心血管疾病等自身免疫性疾病的日益流行預計將顯著增加對可用於藥物輸送系統的聚合物的需求。 例如，世界衛生組織（WHO）估計，癌症將成為2020年全球約1000萬人死亡的主要原因，全球確診的男性癌症患者為9,342,957人，佔癌症患者的15.4%。 與此同時，根據世界癌症研究基金會的數據，2020 年將有 8,751,759 名女性被診斷出患有癌症。

市場趨勢：

  • Phosphorex 和 Dolomite Microfluidics 於 2021 年 6 月合作，結合雙方在疫苗和藥物開發方面的專業知識。 此次合作的目標是創建聚合物和脂質納米顆粒。
  • 2022 年 4 月，CD Bioarticles 宣布推出多種藻酸鹽產品以支持藥物輸送研究。 它們可以用胺基修飾或用生物素標記，僅供實驗室使用。 藻酸鹽是由線性共聚物和古洛醣醛酸單元形成的天然聚合物。
  • 2022 年3 月，贏創宣布推出EUDRATEC，其中包括EUDRAGIT 功能性聚合物等口服輔料、即裝型功能膠囊EUDRACAPTM 以及增強藥物性能的技術和服務。推出了SoluFlow，補充了贏創醫療保健的口服輔料組合藥物輸送系統解決方案。

北美在2021年全球藥物輸送聚合物市場中佔有很大份額。

藥物輸送聚合物市場按地區分為北美、南美、歐洲、中東/非洲和亞太地區。

美國癌症、糖尿病和心血管疾病等慢性病的患病率很高，這增加了對先進藥物輸送系統的需求。 使用藥物遞送聚合物可以提高藥物的生物利用度、減少副作用並提高患者的依從性。 美國政府還通過各種舉措推廣先進的藥物輸送系統，包括《21 世紀治愈法案》和 FDA 的快速嚴重疾病計劃。 這些舉措簡化了創新藥物輸送系統的監管審批流程，使公司更容易將新產品推向市場。 此外，藥物輸送技術的重大進步，例如生物可降解聚合物、基於納米技術的藥物輸送系統和控釋製劑的開發，正在提高藥物的功效和安全性。 這些創新有助於擴大使用基於聚合物的藥物輸送系統可輸送的藥物範圍。

對自我給藥的需求不斷增長，導致了易於使用的藥物輸送系統的開發，例如吸入器、注射器和透皮貼劑，這些系統可以提高患者的依從性，並通過減少住院次數來降低醫療費用。曾是。 此外，對藥物輸送系統研發活動的大量投資預計將促進創新並將新產品推向市場。

內容

第 1 章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場細分
  • 貨幣
  • 先決條件
  • 基準年和預測年的時間表

第 2 章研究方法

  • 調查數據
  • 調查過程

第 3 章執行摘要

  • 研究亮點

第 4 章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
  • 行業價值鏈分析

第 5 章藥物輸送聚合物市場：按材料類型

  • 簡介
  • PLGA（乳酸乙醇酸共聚物）
  • PGA（聚-L-谷氨酸）
  • 聚乳酸（可生物降解）
  • 溫度響應聚合物
  • 有機聚合物
  • 其他

第 6 章藥物輸送聚合物市場：按藥物輸送應用劃分

  • 簡介
  • 擴散有限
  • 溶劑活化
  • 生物降解性/化學控制
  • 外部觸發因素（pH 值、溫度等）

第 7 章藥物輸送聚合物市場：按最終用戶劃分

  • 簡介
  • 學術研究所
  • 醫院
  • 製藥公司

第 8 章藥物輸送聚合物市場：按地區

  • 簡介
  • 北美
    • 按材料類型
    • 按藥物輸送應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按材料類型
    • 按藥物輸送應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按材料類型
    • 按藥物輸送應用
    • 按最終用戶
    • 按國家/地區
  • 中東和非洲
    • 按材料類型
    • 按藥物輸送應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按材料類型
    • 按藥物輸送應用
    • 按最終用戶
    • 按國家/地區

第 9 章競爭格局與分析

  • 主要公司及戰略分析
  • 新興公司和市場盈利能力
  • 併購 (M&A)、合同、合作
  • 供應商競爭力矩陣

第 10 章公司簡介

  • Adhex Pharma
  • Chempilots a/s
  • Bezwada Biomedical, LLC.
  • POLYVATION BV
  • Poly-Med, Inc.
  • Henkel Corporation
  • Evonik Industries AG
  • ULTROXA（R）Polymers
  • IBMM/PHBM
  • Serina Therapeutics
  • The Lubrizol Corporation
簡介目錄
Product Code: KSI061612193

The drug delivery polymer market is predicted to grow at a CAGR of 7.55% from US$18.290 billion in 2021 to US$30.444 billion by 2028.

Polymers have played an important part in improving drug delivery methods by allowing for the controlled release of medications in regular doses over lengthy periods. Due to their biodegradability and biocompatibility, these have been increasingly used in biomedical applications in recent years. However, using polymers as carriers of drugs has significant difficulties, such as complex manufacturing and characterization processes. An important aspect of the biopharmaceutical sector is polymer-based drug delivery, in which a drug, protein, or antibody is covalently bonded to a linear or branched-chain polymer.

Further, the market for drug delivery polymer is anticipated to experience growth throughout the forecast period due to rising research and development activities in the field of nanotechnology to create novel nano-medicines, an expanding product pipeline, a favorable research environment, and an increase in the prevalence of chronic diseases like cancer and diabetes mellitus. However, the market is projected to face challenges throughout the forecast period due to high pharmaceutical research costs and strict regulatory environments.

The drug delivery polymer market is driven by the rising prevalence of chronic diseases.

The rising prevalence of diseases worldwide is anticipated to result in a growing demand for secure and efficient drug-delivery systems. There is expected to be a significant increase in demand for polymers that can be used in drug delivery systems due to the increased prevalence of autoimmune diseases such as cancer, diabetes, and cardiovascular disease. For instance, the World Health Organisation estimates that cancer will be the primary cause of roughly 10 million deaths worldwide in 2020, with which cancer cases in men were 9,342,957 contributing to 15.4% of the global cancer cases diagnosed. In contrast, females were diagnosed with 8,751,759 cancer cases in 2020, as per World Cancer Research Fund International.

Market Developments:

  • Phosphorex and Dolomite Microfluidics partnered in June 2021 to combine their expertise in developing vaccines and medications. The partnership's goal is to create polymeric nanoparticles and lipid nanoparticles.
  • CD Bioparticles announced several alginates products in April 2022 to support drug delivery research. They can be modified with amine groups or marked with biotin and are only meant for use in laboratory research. Alginates are naturally occurring polymers formed of linear copolymers and guluronic acid units.
  • In March 2022, Evonik launched EUDRATEC® SoluFlow, which contains oral excipients such as EUDRAGIT® functional polymers, the ready-to-fill functional capsules EUDRACAPTM, along with technologies and services to enhance drug performance, which complements the Evonik Health Care portfolio of oral drug delivery system solutions.

North America accounted for a major share of the global drug delivery polymer market in 2021.

The drug delivery polymer market has been segmented by geography into North America, South America, Europe, Middle East and Africa, and Asia Pacific.

The USA has a high prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, which has led to an increased demand for advanced drug delivery systems. Using drug-delivery polymers helps improve the bioavailability of drugs, reduces side effects, and enhances patient compliance. Also, the US government has been promoting advanced drug delivery systems through various initiatives, such as the 21st Century Cures Act and the FDA's Expedited Programs for Serious Conditions. These initiatives have streamlined the regulatory approval process for innovative drug delivery systems, making it easier for companies to bring new products to market. Moreover, there have been significant advancements in drug delivery technologies, such as the development of biodegradable polymers, nanotechnology-based drug delivery systems, and controlled-release formulations, which have improved the efficacy and safety of drugs. These innovations have helped to expand the range of drugs that can be delivered using polymer-based drug delivery systems.

The growing demand for self-administration of drugs has resulted in the development of user-friendly drug delivery systems such as inhalers, injectors, and transdermal patches, which have improved patient compliance and reduced healthcare costs by decreasing hospitalization. Furthermore, significant investments in research and development activities focused on drug delivery systems are expected to drive innovation and bring new products to market.

Market Segmentation:

BY MATERIAL TYPE

  • PLGA (Polylactic-co-glycolic acid)
  • PGA (Poly-l-glutamic acid)
  • Polylactic acid (Biodegradable)
  • Temperature-responsive polymer
  • Organic polymer
  • Others

BY DRUG DELIVERY APPLICATION

  • Diffusion-controlled
  • Solvent activated
  • Biodegradable or chemically controlled
  • Externally triggered (i.e., pH, temperature, etc.)

BY END-USER

  • Academic and Research Institutes
  • Hospitals
  • Pharmaceutical Companies

BY GEOGRAPHY

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. DRUG DELIVERY POLYMER MARKET, BY MATERIAL TYPE

  • 5.1. Introduction
  • 5.2. PLGA (Polylactic-co-glycolic acid)
  • 5.3. PGA (Poly-l-glutamic acid)
  • 5.4. Polylactic acid (Biodegradable)
  • 5.5. Temperature-responsive polymer
  • 5.6. Organic polymer
  • 5.7. Others

6. DRUG DELIVERY POLYMER MARKET, BY DRUG DELIVERY APPLICATION

  • 6.1. Introduction
  • 6.2. Diffusion-controlled
  • 6.3. Solvent activated
  • 6.4. Biodegradable or chemically controlled
  • 6.5. Externally triggered (i.e., pH, temperature, etc.)

7. DRUG DELIVERY POLYMER MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Academic and Research Institutes
  • 7.3. Hospitals
  • 7.4. Pharmaceutical Companies

8. DRUG DELIVERY POLYMER MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Material Type
    • 8.2.2. By Drug Delivery Application
    • 8.2.3. By End User
    • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Material Type
    • 8.3.2. By Drug Delivery Application
    • 8.3.3. By End User
    • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Material Type
    • 8.4.2. By Drug Delivery Application
    • 8.4.3. By End User
    • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Material Type
    • 8.5.2. By Drug Delivery Application
    • 8.5.3. By End User
    • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. Israel
    • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Material Type
    • 8.6.2. By Drug Delivery Application
    • 8.6.3. By End User
    • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Adhex Pharma
  • 10.2. Chempilots a/s
  • 10.3. Bezwada Biomedical, LLC.
  • 10.4. POLYVATION BV
  • 10.5. Poly-Med, Inc.
  • 10.6. Henkel Corporation
  • 10.7. Evonik Industries AG
  • 10.8. ULTROXA® Polymers
  • 10.9. IBMM/PHBM
  • 10.10. Serina Therapeutics
  • 10.11. The Lubrizol Corporation